Intellia Therape Financials
Intellia Therape (NTLA) reported $67.7M in revenue for fiscal year 2025, up 16.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Intellia still operates as a research-funded enterprise, with cash burn driven by R&D and buffered by liquidity.
Losses are turning into cash outflow almost one-for-one: FY2025 net loss of$412.7M sat close to operating cash outflow of$394.7M , so the deficit is largely cash spending rather than accounting noise. Because R&D ran at$388.9M against just$67.7M of revenue, this is still a research spending model rather than a business being funded by customers.
Assets shrank to
Customer revenue has not reached self-funding scale: FY2025 free cash outflow of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Intellia Therape's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Intellia Therape scores 0.78, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.7B) relative to total liabilities ($170.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Intellia Therape passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Intellia Therape reported a net loss of $412.7M while operations used $394.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Intellia Therape generated $67.7M in revenue in fiscal year 2025. This represents an increase of 16.9% from the prior year.
Intellia Therape's EBITDA was -$431.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17.7% from the prior year.
Intellia Therape reported -$412.7M in net income in fiscal year 2025. This represents an increase of 20.5% from the prior year.
Intellia Therape earned -$3.81 per diluted share (EPS) in fiscal year 2025. This represents an increase of 27.4% from the prior year.
Cash & Balance Sheet
Intellia Therape recorded an outflow of $395.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 11.6% from the prior year.
Intellia Therape held $155.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Intellia Therape's ROE was -61.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Intellia Therape invested $388.9M in research and development in fiscal year 2025. This represents a decrease of 16.6% from the prior year.
Intellia Therape invested $1.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 80.5% from the prior year.
Not reported for fiscal year 2025.
NTLA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.5M | $67.7M+16.9% | $57.9M+59.6% | $36.3M-30.4% | $52.1M+57.7% | $33.1M-43.0% | $58.0M+34.5% | $43.1M+41.6% | $30.4M+16.5% | $26.1M+58.5% | $16.5M | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $33.1M-43.0% | $58.0M+34.5% | $43.1M+41.6% | $30.4M | N/A | N/A | N/A |
| R&D Expenses | $346.7M | $388.9M-16.6% | $466.3M+7.2% | $435.1M+3.6% | $420.0M+82.8% | $229.8M+52.8% | $150.4M+38.7% | $108.4M+21.7% | $89.1M+31.7% | $67.6M+112.5% | $31.8M+185.0% | $11.2M |
| SG&A Expenses | $136.3M | $119.8M-4.8% | $125.8M+8.0% | $116.5M+29.0% | $90.3M+27.0% | $71.1M+61.0% | $44.2M+7.6% | $41.1M+27.6% | $32.2M+14.9% | $28.0M+66.8% | $16.8M+102.8% | $8.3M |
| Operating Income | -$423.5M | -$441.0M+17.5% | -$534.3M-3.7% | -$515.3M-12.5% | -$458.2M-71.1% | -$267.9M-96.1% | -$136.6M-28.4% | -$106.4M-17.1% | -$90.9M-30.6% | -$69.6M-116.3% | -$32.2M-139.8% | -$13.4M |
| Income Tax | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0+100.0% | -$1.0M |
| Net Income | -$400.0M | -$412.7M+20.5% | -$519.0M-7.9% | -$481.2M-1.5% | -$474.2M-77.0% | -$267.9M-99.6% | -$134.2M+71.7% | -$474.2M-455.6% | -$85.3M-26.4% | -$67.5M-113.5% | -$31.6M-155.2% | -$12.4M |
| EPS (Diluted) | — | -$3.81+27.4% | -$5.25+3.1% | -$5.42+12.0% | -$6.16-63.0% | -$3.78-57.5% | -$2.40 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NTLA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $842.1M-29.3% | $1.2B-8.5% | $1.3B-14.4% | $1.5B+17.4% | $1.3B+91.4% | $676.3M+102.3% | $334.3M-3.8% | $347.3M-7.7% | $376.2M+25.8% | $299.0M+264.0% | $82.1M |
| Current Assets | $527.7M-17.5% | $639.9M-35.9% | $998.3M-18.0% | $1.2B+58.2% | $769.3M+24.8% | $616.5M+113.0% | $289.5M-10.9% | $325.0M-8.4% | $354.8M+26.1% | $281.3M+262.4% | $77.6M |
| Cash & Equivalents | $155.5M-17.8% | $189.2M-16.6% | $226.7M-56.7% | $523.5M+324.2% | $123.4M-22.9% | $160.0M+179.6% | $57.2M-2.8% | $58.9M-82.7% | $340.7M+24.8% | $273.1M+260.2% | $75.8M |
| Accounts Receivable | $9.5M+11.2% | $8.5M-76.6% | $36.5M+867.5% | $3.8M+85.5% | $2.0M-4.6% | $2.1M-53.9% | $4.6M-38.8% | $7.5M-27.9% | $10.5M+62.2% | $6.5M+545.4% | $1.0M |
| Total Liabilities | $170.7M-46.5% | $319.1M+27.2% | $250.8M-11.9% | $284.5M+11.9% | $254.2M+70.3% | $149.3M+131.8% | $64.4M-7.2% | $69.4M-8.3% | $75.6M-15.1% | $89.1M-13.7% | $103.3M |
| Current Liabilities | $103.9M-6.3% | $110.9M-3.8% | $115.2M-9.0% | $126.6M+0.6% | $125.8M+95.8% | $64.3M+80.3% | $35.6M-12.2% | $40.6M+29.4% | $31.4M+2.0% | $30.7M+187.3% | $10.7M |
| Total Equity | $671.4M-23.0% | $872.0M-17.0% | $1.1B-15.0% | $1.2B+18.8% | $1.0B+97.4% | $527.1M+95.3% | $269.9M-2.9% | $277.9M-7.5% | $300.6M+43.3% | $209.8M+1089.8% | -$21.2M |
| Retained Earnings | -$2.6B-19.0% | -$2.2B-31.3% | -$1.7B-40.9% | -$1.2B-67.5% | -$703.0M-61.6% | -$435.1M-44.6% | -$300.9M-49.7% | -$201.0M-66.0% | -$121.1M-126.1% | -$53.6M-144.2% | -$21.9M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
NTLA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$346.6M | -$394.7M-13.1% | -$348.9M+11.5% | -$394.1M-18.2% | -$333.3M-48.1% | -$225.0M-350.9% | -$49.9M+51.7% | -$103.2M-68.5% | -$61.3M+6.2% | -$65.3M-280.8% | $36.1M+2148.2% | -$1.8M |
| Capital Expenditures | $2.0M | $1.1M-80.5% | $5.8M-58.7% | $14.0M+3.1% | $13.6M+6.3% | $12.8M+255.8% | $3.6M-47.2% | $6.8M+6.9% | $6.4M-37.0% | $10.1M+63.7% | $6.2M+141.4% | $2.6M |
| Free Cash Flow | -$348.7M | -$395.9M-11.6% | -$354.7M+13.1% | -$408.1M-17.7% | -$346.8M-45.9% | -$237.8M-344.5% | -$53.5M+51.4% | -$110.0M-62.7% | -$67.6M+10.3% | -$75.4M-351.7% | $29.9M+793.6% | -$4.3M |
| Investing Cash Flow | -$48.5M | $228.0M+81.6% | $125.6M+500.6% | -$31.3M-119.6% | $160.3M+129.1% | -$550.8M-156.8% | -$214.5M-952.0% | $25.2M+109.7% | -$260.8M-2484.3% | -$10.1M-63.7% | -$6.2M | N/A |
| Financing Cash Flow | $346.5M | $131.5M-29.2% | $185.7M+42.5% | $130.3M-77.6% | $583.0M-20.9% | $736.7M+98.2% | $371.8M+386.4% | $76.4M+90.1% | $40.2M-71.9% | $143.0M-14.5% | $167.3M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NTLA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0% | N/A | N/A | N/A |
| Operating Margin | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | -266.3% | -195.2% | N/A |
| Net Margin | -609.8% | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -1100.1% | -280.4% | -258.6% | -192.0% | N/A |
| Return on Equity | -61.5%-2.0pp | -59.5%-13.7pp | -45.8%-7.4pp | -38.4%-12.6pp | -25.8%-0.3pp | -25.5%+150.2pp | -175.7%-145.0pp | -30.7%-8.2pp | -22.5%-7.4pp | -15.1% | N/A |
| Return on Assets | -49.0%-5.4pp | -43.6%-6.6pp | -37.0%-5.8pp | -31.2%-10.5pp | -20.7%-0.8pp | -19.9%+122.0pp | -141.9%-117.3pp | -24.6%-6.6pp | -17.9%-7.4pp | -10.6%+4.5pp | -15.1% |
| Current Ratio | 5.08-0.7x | 5.77-2.9x | 8.67-0.9x | 9.61+3.5x | 6.11-3.5x | 9.60+1.5x | 8.12+0.1x | 8.01-3.3x | 11.32+2.2x | 9.15+1.9x | 7.26 |
| Debt-to-Equity | 0.25-0.1x | 0.37+0.1x | 0.240.0x | 0.230.0x | 0.240.0x | 0.280.0x | 0.240.0x | 0.250.0x | 0.25-0.2x | 0.42 | N/A |
| FCF Margin | -585.0% | -612.8% | -1124.9% | -665.5% | -719.4% | -92.3% | -255.3% | -222.2% | -288.6% | 181.7% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Intellia Therape Ranks
Frequently Asked Questions
What is Intellia Therape's annual revenue?
Intellia Therape (NTLA) reported $67.7M in total revenue for fiscal year 2025. This represents a 16.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Intellia Therape's revenue growing?
Intellia Therape (NTLA) revenue grew by 16.9% year-over-year, from $57.9M to $67.7M in fiscal year 2025.
Is Intellia Therape profitable?
No, Intellia Therape (NTLA) reported a net income of -$412.7M in fiscal year 2025.
What is Intellia Therape's EBITDA?
Intellia Therape (NTLA) had EBITDA of -$431.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Intellia Therape's return on equity (ROE)?
Intellia Therape (NTLA) has a return on equity of -61.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Intellia Therape's free cash flow?
Intellia Therape (NTLA) recorded an outflow of $395.9M in free cash flow during fiscal year 2025. This represents a -11.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Intellia Therape's operating cash flow?
Intellia Therape (NTLA) recorded an outflow of $394.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Intellia Therape's total assets?
Intellia Therape (NTLA) had $842.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Intellia Therape's capital expenditures?
Intellia Therape (NTLA) invested $1.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Intellia Therape spend on research and development?
Intellia Therape (NTLA) invested $388.9M in research and development during fiscal year 2025.
What is Intellia Therape's current ratio?
Intellia Therape (NTLA) had a current ratio of 5.08 as of fiscal year 2025, which is generally considered healthy.
What is Intellia Therape's debt-to-equity ratio?
Intellia Therape (NTLA) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Intellia Therape's return on assets (ROA)?
Intellia Therape (NTLA) had a return on assets of -49.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Intellia Therape's cash runway?
Based on fiscal year 2025 data, Intellia Therape (NTLA) had $155.5M in cash against an annual operating cash burn of $394.7M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Intellia Therape's Altman Z-Score?
Intellia Therape (NTLA) has an Altman Z-Score of 0.78, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Intellia Therape's Piotroski F-Score?
Intellia Therape (NTLA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Intellia Therape's earnings high quality?
Intellia Therape (NTLA) reported a net loss of $412.7M while operations used $394.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Intellia Therape?
Intellia Therape (NTLA) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.